Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants

Petri, Boris; Bootz, Alexander; Khalansky, A. S.; Hekmatara, T.; Müller, Rainer H.; Uhl, Reiner; Kreuter, Jörg; Gelperina, Svetlana

doi:10.1016/j.jconrel.2006.10.015

Cited by 281 publications

(175 citation statements)

References 27 publications

Supporting

Mentioning

169

Contrasting

Unclassified

Order By: Relevance

“…7,87 The only evidence was achieved by 2-D electrophoresis (2-D PAGE) showing that PBCA NPs coated with polaxamer 188 (Pluronic F68 Ò ) and Ps80 showed a considerable adsorption of apolipoprotein A-I (ApoA-I), leading to a possible interaction with BBB receptors. This finding could induce to propose a general pathway for BBB crossing of PBCA coated Ps80 (or Pluorinc), based on a great absorption of APO A-I allowing a receptor-mediated transcytosis.…”

Section: Alzheimer Diseasementioning

confidence: 99%

Nanoparticle transport across the blood brain barrier

et al. 2016

View full text Add to dashboard Cite

While the role of the blood-brain barrier (BBB) is increasingly recognized in the (development of treatments targeting neurodegenerative disorders, to date, few strategies exist that enable drug delivery of non-BBB crossing molecules directly to their site of action, the brain. However, the recent advent of Nanomedicines may provide a potent tool to implement CNS targeted delivery of active compounds. Approaches for BBB crossing are deeply investigated in relation to the pathology: among the main important diseases of the CNS, this review focuses on the application of nanomedicines to neurodegenerative disorders (Alzheimer, Parkinson and Huntington's Disease) and to other brain pathologies as epilepsy, infectious diseases, multiple sclerosis, lysosomal storage disorders, strokes.

show abstract

Section: Alzheimer Diseasementioning

confidence: 99%

Nanoparticle transport across the blood brain barrier

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Different drugs such as dalargin and loperamide are loaded on NPs by simple absorption. Additionally, methotrexate or doxorubicin are attached to NPs by adding during the process of polymerization [31,32]. Moreover, such NPs have two interesting features make them appropriate candidates for drug delivery systems.…”

Section: Discussionmentioning

confidence: 99%

Polybutylcyanoacrylate Nanoparticles and Drugs of the Platinum Family: Last Status

et al. 2013

View full text Add to dashboard Cite

Cisplatinum and carboplatinum drugs from platinum-containing family are anti-cancer drugs. Using these drugs causes side effects. Targeted and selective prescription decreases side effects of the drugs. This can be achieved using nanotechnology. In this study, cisplatinum and carboplatinum drugs were loaded on polybutylcyanoacrylate nanoparticles using emulsion polymerization method. To determine amount of loaded drug onto nanoparticle, spectrophotometry method was used. Evaluation of cytotoxicity of such nanoparticles was performed on MCF-7 cell line using MTT assay. Loading percentage of cisplatinum and carboplatinum drugs on nanoparticles were estimated 4 and 6 %, respectively. Cytotoxicity survival rate for cisplatinum and nanoparticle containing cisplatinum at the lowest concentration (p \ 0.01) (20 lM) were estimated 64 ± 1 and 67 ± 0.5 %, respectively. These values at the highest concentration (p \ 0.01) (160 lM) were measured 28 ± 0.7 and 31 ± 0.4 %. Additionally for carboplatinum and nanoparticles containing carboplatinum at the concentration (p \ 0.01) (20 lM) amounts were estimated to be 80 ± 0.6 and 84 ± 0.6 %, while at the concentration (p \ 0.01) (160 lM) were identified to be 44 ± 0.5 and 51 ± 0.2 %, respectively. Probably, due to low level of loading, cytotoxicity of both drugs at nano particle status was decreased in comparison with their standard form.

show abstract

“…The authors found that GHRH antagonists (MZ-5-156 and JV-1-36) reduce the tumorigenicity and growth of U87MG human glioblastoma cells transplanted onto mouse flanks and found that the peripheral administration of the iodinated GHRH antagonist JV-1-42 rapidly crosses the blood-brain barrier (37). In order to obtain effective intratumoral concentrations of GnRH agonists, another chance is to develop different routes of administration which can circumvent the blood-brain barrier (gene therapy, nanoparticles) (38). Based on the observation that GnRH agonists have significant anti-glioblastoma activity in cell cultures, further evaluation of their potential preventive or therapeutic utility in vivo is at present ongoing in our laboratory.…”

Section: Discussionmentioning

confidence: 99%

Novel insights into GnRH receptor activity: Role in the control of human glioblastoma cell proliferation

Marelli

Moretti²,

Mai³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Malignant glioblastoma is one of the highest proliferative and invasive tumors within the central nervous system (CNS); the therapeutical options for this disease are still very poor. Receptors for gonadotropin-releasing hormone (GnRH) have been reported to be present in glioblastoma tissues. This study aimed to determine the role of these receptors in the control of glioma growth. In two human glioblastoma cell lines, U87MG and U373, we demonstrated the expression of GnRH receptors, both at mRNA and protein levels. We also found that GnRH receptor is expressed in glioblastoma tissues from tumor patients as shown by Western blotting. In U87MG and U373 cell lines, we found the expression of mRNA for GnRH, indicating the presence of an autocrine GnRH-based system in these cell lines. Treatment of the two cell lines with a GnRH agonist resulted in a significant decrease of cell proliferation. Moreover, the GnRH agonist significantly counteracted the forskolin-induced increase of intracellular cAMP levels in these cells. These findings suggest that the GnRH receptor might represent a molecular target for an endocrine therapeutical approach against gliomas.

show abstract

Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants

Cited by 281 publications

References 27 publications

Nanoparticle transport across the blood brain barrier

Nanoparticle transport across the blood brain barrier

Polybutylcyanoacrylate Nanoparticles and Drugs of the Platinum Family: Last Status

Novel insights into GnRH receptor activity: Role in the control of human glioblastoma cell proliferation

Contact Info

Product

Resources

About